These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22621180)

  • 41. RimabotulinumtoxinB vs. onabotulinumtoxinA for the treatment of forehead lines: an evaluator-blind, randomized, pilot study.
    Lee DH; Kang SM; Feneran A; Youn CS; Kim JK; Cho S; Won CH; Chang SE; Lee MW; Choi JH; Moon KC
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e1-7. PubMed ID: 23030660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines.
    Glogau R; Blitzer A; Brandt F; Kane M; Monheit GD; Waugh JM
    J Drugs Dermatol; 2012 Jan; 11(1):38-45. PubMed ID: 22206075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term treatment of glabellar rhytides using onabotulinumtoxina.
    Dailey RA; Philip A; Tardie G
    Dermatol Surg; 2011 Jul; 37(7):918-28. PubMed ID: 21575099
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants.
    Brin MF; Boodhoo TI; Pogoda JM; James LM; Demos G; Terashima Y; Gu J; Eadie N; Bowen BL
    J Am Acad Dermatol; 2009 Dec; 61(6):961-70.e1-11. PubMed ID: 19744746
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.
    Moy R; Maas C; Monheit G; Huber MB;
    Arch Facial Plast Surg; 2009; 11(2):77-83. PubMed ID: 19289677
    [TBL] [Abstract][Full Text] [Related]  

  • 46. OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study.
    Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Weichman BM; Garcia JK
    Dermatol Surg; 2019 May; 45(5):689-699. PubMed ID: 31034447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.
    Hexsel D; Brum C; do Prado DZ; Soirefmann M; Rotta FT; Dal'Forno T; Rodrigues TC
    J Am Acad Dermatol; 2012 Aug; 67(2):226-32. PubMed ID: 22041253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of administering abobotulinumtoxinA through a single injection point when treating lateral periocular rhytides.
    Kiripolsky MG; Goldman MP
    J Cosmet Dermatol; 2011 Sep; 10(3):232-4. PubMed ID: 21896136
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Rzany BJ; Ascher B; Avelar RL; Bergdahl J; Bertucci V; Bodokh I; Carruthers JA; Cartier H; Delmar H; Denfeld R; Gross JE; Heckmann M; Hedén P; Hilton S; Inglefield C; Ogilvie P; Sattler G; Sebastian M; Solish N; Swift A; Trévidic P
    Aesthet Surg J; 2020 Mar; 40(4):413-429. PubMed ID: 30951166
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Duration of Clinical Efficacy of OnabotulinumtoxinA in Crow's Feet Lines: Results from Two Multicenter, Randomized, Controlled Trials.
    Baumann L; Dayan S; Connolly S; Silverberg N; Lei X; Drinkwater A; Gallagher CJ
    Dermatol Surg; 2016 May; 42(5):598-607. PubMed ID: 27110893
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A two-center, open-label, randomized, split-face study to assess the efficacy and safety of one versus three intradermal injection sites of abobotulinumtoxinA in the treatment of lateral periocular rhytides.
    Fabi SG; Sundaram H; Guiha I; Goldman MP
    J Drugs Dermatol; 2013 Aug; 12(8):932-7. PubMed ID: 23986168
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes.
    Carruthers A; Carruthers J
    J Drugs Dermatol; 2009 Oct; 8(10):924-9. PubMed ID: 19852121
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.
    Denys P; Le Normand L; Ghout I; Costa P; Chartier-Kastler E; Grise P; Hermieu JF; Amarenco G; Karsenty G; Saussine C; Barbot F;
    Eur Urol; 2012 Mar; 61(3):520-9. PubMed ID: 22036776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multicenter, randomized, parallel-group study of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation: satisfaction and patient-reported outcomes.
    Carruthers J; Carruthers A; Monheit GD; Davis PG
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2135-45. PubMed ID: 21070457
    [TBL] [Abstract][Full Text] [Related]  

  • 56. OnabotulinumtoxinA for the treatment of a "gummy smile".
    Suber JS; Dinh TP; Prince MD; Smith PD
    Aesthet Surg J; 2014 Mar; 34(3):432-7. PubMed ID: 24676413
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does Increasing the Dose of Abobotulinumtoxina Impact the Duration of Effectiveness for the Treatment of Moderate to Severe Glabellar Lines?
    Joseph JH; Eaton LL; Robinson J; Pontius A; Williams EF
    J Drugs Dermatol; 2016 Dec; 15(12):1544-1549. PubMed ID: 29106437
    [TBL] [Abstract][Full Text] [Related]  

  • 58. OnabotulinumtoxinA for Simultaneous Treatment of Upper Facial Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Study.
    Rivkin AZ; Ogilvie P; Dayan S; Yoelin SG; Weichman BM; Garcia JK
    Dermatol Surg; 2020 Jan; 46(1):50-60. PubMed ID: 30829771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.
    Kuo HC; Liao CH; Chung SD
    Eur Urol; 2010 Dec; 58(6):919-26. PubMed ID: 20864251
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?
    Carruthers A; Carruthers J; Cohen J
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S97-104. PubMed ID: 17241422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.